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Available online 24 February 2016High-mobility group box 1 (HMGB1) is a nuclear and cytosolic protein that is released during tissue damage from
immune and non-immune cells— includingmicroglia and neurons. HMGB1 can contribute to progression of nu-
merous chronic inﬂammatory and autoimmune diseaseswhich ismediated in part by interactionwith the recep-
tor for advanced glycation endproducts (RAGE). There is increasing evidence from in vitro studies that HMGB1
may link the twomain pathophysiological components of Parkinson's disease (PD), i.e. progressive dopaminergic
degeneration and chronic neuroinﬂammation which underlie the mechanistic basis of PD progression.
Analysis of tissue and bioﬂuid samples from PD patients, showed increasedHMGB1 levels in human postmortem
substantia nigra specimens aswell as in the cerebrospinal ﬂuid and serum of PD patients. In amousemodel of PD
induced by sub-acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), systemic admin-
istration of neutralizing antibodies to HMGB1 partly inhibited the dopaminergic cell death, and reduced the in-
crease of RAGE and tumour necrosis factor-alpha. The small natural molecule glycyrrhizin, a component from
liquorice root which can directly bind to HMGB1, both suppressed MPTP-induced HMGB1 and RAGE upregula-
tion while reducing MPTP-induced dopaminergic cell death in a dose dependent manner.
These results provide ﬁrst in vivo evidence that HMGB1 serves as a powerful bridge between progressive dopa-
minergic neurodegeneration and chronic neuroinﬂammation in a model of PD, suggesting that HMGB1 is a suit-
able target for neuroprotective trials in PD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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. This is an open access article under1. Introduction
Occurrence of chronic inﬂammation in Parkinson's disease (PD) is
increasingly recognized (Hirsch and Hunot, 2009, Teismann and
Schulz, 2004), and recent studies argue in favour of a central role for
chronic inﬂammation in disease progression in different PD models
(Gao et al., 2003, Zhang et al., 2010). The basic idea emerging from
these observations is as follows: neurons can sustain a certain level of
inﬂammatory challenge; however, if the inﬂammatory process is
prolonged and levels of neurodegeneration exceed a certain threshold;
death of neurons, accumulation of protein aggregates, and unregulated
neuroinﬂammation potentiate each other almost independently of the
initial cause of neurodegeneration (Gao et al., 2011, Hirsch et al.,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
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dysregulated parainﬂammation (Medzhitov, 2008, Xu et al., 2009).
High-mobility group box 1 (HMGB1) is a non-histone DNA binding
protein, which stabilizes nucleosome formation indirectly, and regu-
lates the interaction of transcription factors with DNA (Bustin and
Reeves, 1996). HMGB1 can be secreted actively from inﬂammatory
cells but is released in greater amounts passively fromdying cells during
tissue damage and inﬂammatory disease and can then act as a damage
associated molecular pattern (DAMP) to initiate inﬂammatory re-
sponses (Andersson and Tracey, 2011). This mechanism may be partic-
ularly relevant for PD as a recent study elegantly demonstrated that: by
use of cell models reﬂecting PD pathophysiology HMGB1 signalling in-
deed triggered progressive dopaminergic neurodegeneration by uncon-
trolled chronic inﬂammation (Gao et al., 2011). The underlying
mechanisms of action are the increased expression of HMGB1-binding
multi-ligand receptors, which are mainly located on the surface of
cells of the innate immune system (Andersson et al., 2008) and the ac-
tivation of these receptors due to translocation of HMGB1 to the cytosol
(Lu et al., 2014). HMGB1 binds to receptor for advanced glycation end
products (RAGE) (Andersson et al., 2008, Scafﬁdi et al., 2002), Toll-like
receptors 2 (TLR2) and 4 (TLR4) (Andersson et al., 2008, Wahamaa
et al., 2011) and macrophage antigen complex 1 (Mac1) (Gao et al.,
2011). Of these, the RAGE-HMGB1 interaction has been shown to be
pathogenetic, e.g. in models of ischemic injury (Kim et al., 2006) and
Alzheimer's disease (Mazarati et al., 2011).
Most recently, a study focusing on the cause of tissue damage during
subarachnoid haemorrhage (Sun et al., 2013) suggested that the delete-
rious effects of released HMGB1 can be modulated by naturally occur-
ring anti-inﬂammatory compounds such as glycyrrhizin. Glycyrrhizin
may be a particularly interesting target compound for neuromodulation
in PD, as it is a commonly used sweetener and generally recognized as
safe when not excessively consumed (Isbrucker and Burdock, 2006).
The European Union suggests that up to 100 mg of glycyrrhizic acid a
day, which equals approximately 50 g of liquorice sweets (Stormer
et al., 1993) do not represent any health hazard for humans.
Based on these data, and on our recent observation that a second
RAGE ligand, S100B, has deleterious effects in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-model (Sathe et al., 2012), we
have explored the role of HMGB1 in the MPTP model as well as in
biospecimens from PD patients.
We have found that HMGB1 is up-regulated in the substantia nigra
(SN), the cerebrospinal ﬂuid (CSF) and the serum of PD patients, as
well as in MPTP-treated mice. In addition, blockade of HMGB1 with a
neutralizing antibody in the MPTP model led to reduced levels of ex-
pression and activation of both HMGB1 and RAGE associated with re-
duced gliosis on histological examination, suggesting that, inhibition
of HMGB1 may be neuroprotective. Furthermore, we found that the li-
quorice constituent glycyrrhizin also reduced HMGB1 expression and
appeared to be neuroprotective in the MPTP-model.Demographic, clinical and biochemical data of the 122 participants donating CSF and se-
rum for HMGB1 protein analysis.
PD Controls P value
Individuals (f) 75 (53) 47 (27) 1.00
Age at examination [years] 64 ± 9 61 ± 11 0.04
Aao parkinsonism [years] 59 ± 10
Parkinson duration [years] 5.5 ± 5.0
Hoehn & Yahr stage (0–5) 2 ± 1
CSF albumin [pg/mL] 249 ± 84 236 ± 81 0.43
CSF Abeta1–42 [pg/mL] 784 ± 289 762 ± 325 0.74
CSF total tau [pg/mL] 198 ± 117 221 ± 136 0.38
CSF phospho-tau [pg/mL] 40 ± 16 42 ± 18 0.44
CSF HMGB1 [ng/mL] 1.14 ± 2.65 0.20 ± 0.74 0.009
Serum HMGB1 [ng/mL] 2.58 ± 2.69 1.59 ± 1.73 0.010
As HMGB1 levels were not normally distributed, they were log-transformed for statistical
analysis. Continuous data are presented with mean ± SEM, dichotomous data with fre-
quency. Signiﬁcance was calculated with Student's t test and Fishers exact test. HMGB1
comparisons were performed using a linear regression model with age as a covariate.
Aao: age at onset.2. Materials and methods
2.1. Human brain tissue collection and processing
Human nigral tissuewas obtained from the Parkinson UK Brain Bank
at Imperial College, London, UK. Selected PD and control samples were
matched for age at death. PD patients (n = 6) were 79 ± 2 (mean ±
SEM) years with an average disease duration of 9 ± 1 years. Age at
onset of diseasewas 70±2 years. None of the PDpatients had a positive
family history of the disease. Control cases (n = 5) were aged 80 ±
3 years at death. Post-mortem delay was 38 ± 10 h in PD samples and
25 ± 10 h in control samples (p = 0.38).
Samples were isolated in NP-40 buffer with protease inhibitors
(Complete Protease Inhibitor Cocktail Tablets, Roche, UK) 1:20 (wt/
vol) and processed by hand homogenisation. Extracts were centrifugedat 14,000 rpm (18,620 ×g; Mikro 200R) for 20min at 4 °C and superna-
tants retained.
2.2. CSF/serum collection, and HMGB1 determination in these body ﬂuids
CSF and serum samples of 75 PD patients and 47 controls collected
between 2010 and 2013 were obtained from the Neuro Biobank of the
University of Tuebingen. PD patients were diagnosed according to cur-
rent criteria (Hughes et al., 1992) by movement disorders specialists.
Controls did not have any signs or symptoms for neurodegenerative
diseases. Twenty of the controls were investigated by spinal tap per-
formed for investigation of lumbar pain; sixteen of the controls
displayed non-speciﬁc symptoms such as headache and mood distur-
bances (exclusive of vascular events), and eleven healthy volunteers
underwent spinal taps as healthy controls in the frame of scientiﬁc stud-
ies. None of the included individuals had a history or clinical signs of in-
ﬂammation. All patients and controls underwent a thorough
neurological examination, and were classiﬁed according to the Hoehn
& Yahr (H&Y) staging. Patients with dementia were not included. De-
mographic and clinical data are given in Table 1. All participants gave
their informed consent, and the local ethical committee approved the
study.
CSF and blood collection as well as determination of routine diag-
nostic parameters were performed according to a standardized protocol
(Maetzler et al., 2011). In brief, spinal taps were performed between
8:00 and 10:00 in the morning under fasting conditions. Samples
were centrifuged and stored at−70 °C within 1 h of sample collection.
Only samples fromdonorswith normal CSF values (b4 cells/μl, CSF albu-
min levels b 500 mg/l) were included. Routine CSF and serum parame-
ters (albumin, immunoglobulin G, cell count) did not differ signiﬁcantly
between PD and controls (Table 1). HMGB1 was measured in duplicate
with a commercially available ELISA kit (ST51011, IBL, under licence of
Shino-Test Corporation), according to the manufacturer's instructions.
The minimum detection level was 0.3 ng/ml.
2.3. Animals, induction of PD-like disease and interventions
Wild type (WT) C57BL6J mice (obtained from Charles River Labora-
tories; 3–6 mice per time point) were injected intraperitoneally (i.p.)
with MPTP (30 mg/kg i.p., Sigma, UK) dissolved in saline, once a day
for over 5 consecutive days. Some animals also received HMGB1-
neutralizing antibody (200 μg) (Yang et al., 2004) i.p. prior to treatment
withMPTP and every third day afterwards. Control mice received saline
only. Glycyrrhizin (16.8 or. 50 mg/kg, Sigma) was administered
i.p. 30 min after the ﬁrst injection of MPTP once daily at 24 h intervals
over the course of the study, the dose was based on previous studies
(Abe et al., 2008, Kim and Lee, 2008).
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tion of MPTP (0, 1, 2, 4, 7, 14, 21 days). For HPLCmeasurements and ty-
rosine hydroxylase (TH) immunohistochemistry, mice were sacriﬁced
21 days after the last MPTP injection. All protocols were in accordance
with the Home Ofﬁce regulations.
2.4. Western blot analysis
Mouse and human brain extracts were prepared and Western blot
analyses performed as described earlier (Sathe et al., 2012). Primary an-
tibodies were: HMGB1 (1:1000, Millipore UK); RAGE (1:1000,
Millipore); S100B (1:1000, Sigma); cyclooxygenase-2 (COX-2) (1:250,
BD Bioscience, UK); tumour necrosis factor-alpha (TNF-α) (1:1000,
Abcam, UK); β-actin (1:25,000, Sigma). Blots were incubated at 4 °C
overnight. Horseradish peroxidase-conjugated secondary antibodies
(anti-rabbit or anti-mouse 1:10,000, Amersham) and ECL solution
(Luminol sodium salt in 0.1 mM Tris HCl and Para-hydroxycoumarin
in DMSO) were used for chemiluminescence detection. Bands were
quantiﬁed using the FluorChem 8800 digital image system (Alpha
Innotech, UK).
2.5. Total RNA extraction and RT-PCR
Total RNA from the ventral midbrain was isolated in Trizol
(Invitrogen, UK). First strand cDNA was analysed using the SuperscriptFig. 3. HMGB1 mRNA and protein levels are upregulated after MPTP treatment. In mice,
real-time PCR and Western blot tests indicate that HMGB1 mRNA and protein levels are
increased at day 1 after MPTP treatment. Within 4 days, HMGB1 protein (A) and mRNA
levels (B) return back to initial values. Data are mean ± SEM, n = 4–6 mice per group.
*p b 0.05; ANOVA with student Newman–Keuls post-hoc test.
Fig. 2.HMGB1 levels in serum and cerebrospinalﬂuid in patientswith Parkinson's disease.
In the immunoassay, HMGB1 levels are signiﬁcantly increased in both serum (A) and CSF
(B) of 75 patients with Parkinson's disease (PD) compared to 47 controls (HC). HMGB1
serum levels of PD patients are negatively correlated with age at onset (C), and
positively with disease duration (D).
Fig. 1. HMGB1 in dopaminergic neurons of human post-mortem substantia nigra (SNpc).
Usingwestern blotting, HMGB1protein levels in SNpc are, as amean, higher in six samples
of Parkinson's disease (PD), compared with ﬁve control samples (A). Double
immunoﬂuorescence studies reveal cytoplasmic HMGB1 localization in TH-positive
dopaminergic neurons of patients with PD (F–I), but not in control patients (B–E).
*p b 0.05. Scale bar = 20 μm.
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then ampliﬁedbypolymerase chain reaction in a 10 μl total reaction vol-
ume using the Roche Light cycler 480. The primermouse sequence used
was as follows: HMGB1 5′-TCGCCTTTGATTTTGGGGCGGT-3′ (forward)
and 5′-AGCTGAGAATGGCTTGGGTCGT-3′ (reverse). As internal control,
β-actin cDNA was co-ampliﬁed using primer sequences 5-TGTGATGG
TGGAATGGGTCAG-3′ (forward) and 5′-TTTGATGTCACGCACGATTTCC-
3′ (reverse). All primers were mouse-speciﬁc and intron-spanning and
were designed based on reported sequences available from the
GENEBANK database. The PCR products were all of the expected size,
and their proper identities were conﬁrmed by automatic sequencing
performed by DNA Sequencing & Services (MRCPPU, College of Life Sci-
ences, University of Dundee, Scotland, www.dnaseq.co.uk) using Ap-
plied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems
model 3730 automated capillary DNA sequencer.
2.6. Immunohistochemistry
Immunostaining was performed according to standardized in-lab
protocols (Sathe et al., 2012). Primary antibodies (in PBS-Triton-NGS)
were: HMGB1 (1:1000, Sigma); glial ﬁbrillary acidic protein (GFAP)
(1:1000, DAKO); TH (1:1000, Millipore) and Iba1 (1:500, WakoFig. 4.Double immunoﬂuorescence reveals localization of HMGB1 in the nucleiwith translocatio
(M–P) in the substantia nigra pars compacta (2d after MPTP). Data are mean ± SEM, n = 4–6Chemicals, Germany). The sections were incubated in anti-rabbit
(1:200, cy3, Jackson Immuno Research, UK) or anti-mouse (1:300,
Alexa Fluor 488 nm,Molecular Probes, UK) ﬂuorescein-conjugated anti-
bodies for visualization using confocal microscopy. Immunohistochem-
istry was carried out as described earlier (Sathe et al., 2012) and
counterstained for Nissl (Thionin, Sigma). TH-, GFAP-, Iba1- and Nissl-
positive cells in the SN pars compacta (SNpc) were counted using the
optical fractionator method with the examiner being blinded towards
treatment group. Striatal density of TH immunoreactivitywasmeasured
as described elsewhere (Sathe et al., 2012). For double immune-
ﬂuorescence microglia were incubated with ﬁrst biotinylated
Lycopersicon esculentum (tomato) lectin. (Vector Laboratories, Peterbor-
ough, UK) and revealed with streptavidin conjugated with DyLight 488
(Vector Laboratories).2.7. HPLC
Levels of 1-methyl-4-phenylpyridinium (MPP+) dopamine and its
metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) were measured in striatal samples as de-
scribed (Sathe et al., 2012).n to the cytosol afterMPTP inGFAP-positive astrocytes (E–H) and Iba-1-positivemicroglia
mice per group. Scale bar = 20 μm.
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Data were analysed with Graphpad Prism (version 5.04) and JMP
software (version 10.0, SAS). All values are expressed as means ± theFig. 5.HMGB1 is translocated into the cytoplasm 1 day after MPTP treatment in dopaminergic n
the nuclei of TH-positive dopaminergic neurons after saline (A–D,white arrow), with a clear tra
mice receiving HMGB1-neutralizing antibody (I–L) or glycyrrhizin (M–P) (2d after MPTP). (Q)
in SNpc. TH-positive cells presenting staining for HMGB1 in the cytoplasm portion were cons
compare to MPTP mice group treated with saline (Newman–Keuls post-hoc test). Data are genstandard error of themean (SEM) or frequency unless stated otherwise.
Differences between means were analysed using Student's t-test (2
groups) and the one-way ANOVA (N2 groups). When ANOVA showed
signiﬁcant differences, pair-wise comparisons between means wereeurons. Double immunoﬂuorescence inmouse midbrain reveals localization of HMGB1 in
nslocation to the cytosol afterMPTP (E–H,white arrows), which is signiﬁcantly reduced in
Stereological cell counting in epiﬂuorescence ﬁeld was performed for TH-positive neurons
idered positive to HMGB1 translocation from nuclei to cytoplasm. *p b 0.05, ***p b 0.001
erated with 5 mice per group. Value are presented with mean ± SEM. Scale bar = 20 μm.
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coefﬁcient was used for correlation analyses, and the Fisher's exact
test for comparison of categorical data. Differences of HMGB1 levels be-
tween PD patients and controls were calculated using a linear regres-
sion model (two effects: PD yes/no, and age), with the likelihood ratio
as outcome. Differences were assumed to be signiﬁcant at p b 0.05
(two-sided).
3. Results
3.1. HMGB1 is detectable in neuronal and glial cells of human post-mortem
tissue, and higher levels are present in PD patients than controls
Immunostaining in the post-mortemmidbrain slices of PD and con-
trol subjects revealed that HMGB1 protein is consistently expressed in
TH-positive neurons within the SNpc (Fig. 1B–I). PD patients regularly
showed cytosolic location of HMGB1 but not controls, indicating trans-
location of HMGB1 into the cytosol in TH-positive neurons (Fig. 1F–I,
white arrow). Immunoblotting yielded signiﬁcantly higher HMGB1pro-
tein levels in the SNpc of PD cases than in those of controls (Fig. 1A). For
additional information double immunoﬂuorescence labelling of HMGB1
along with three different cell markers, TH (Supplemental Fig. 1), GFAP
and Microglial cells (using tomato lectin) (Supplemental Fig. 2) in
human brain tissue was performed.
3.2. Heightened serum and CSF HMGB1 levels in PD
In both serum and CSF of the 122 sample pairs investigated, HMGB1
levels were signiﬁcantly higher in PD patients than in controls (Fig. 2A,
B). In PD patients, serum (p=0.035, Fig. 2C), but not CSF HMGB1 levels
(p= 0.75) correlated negatively with age at onset of the disease. Serum
HMGB1 levels showed a signiﬁcant positive correlationwith disease du-
ration (p= 0.037, Fig. 2D) which was not the case in CSF samples (p=
0.80).Fig. 6.NeutralizingHMGB1 rescues dopaminergic neurons fromMPTP toxicity. Numbers of TH-p
receiving HMGB1-neutralizing antibody (upper panels; A–B). Three weeks after MPTP treatme
positive neurons, than domice not receiving the antibody (lower panel in A and B). Accordingl
weeks after MPTP are signiﬁcantly less severe inmice receiving HMGB1-neutralizing antibody
Scion Corp., Frederick, Maryland, USA). Striatal monoamine levels were assessed by HPLC. *p b
antibody (Newman–Keuls post-hoc test). Data are generated with six mice per group, values aNo relevant associations were detected between histopathological
staging of disease (H&Y stage) and serum (p = 0.52) or CSF HMGB1
levels (p = 0.89), respectively. Table 1 presents details of the demo-
graphic, clinical and biochemical parameters of the cohorts.
3.3. HMGB1 RNA and protein levels are increased after MPTP treatment
In mice, mRNA and protein levels of HMGB1 in the ventral midbrain
(the brain region containing the SNpc) are increased oneday afterMPTP
administration and then returned back to baseline levels (Fig. 3A, B).
Immunohistochemistry conﬁrmed HMGB1 as a protein widely
expressed in astrocytes and microglia (Fig. 4). Dopaminergic neurons
clearly showed enhanced staining for HMGB1, due to increased levels
in the cytosol, indicating that HMGB1 is more actively translocated
from the nucleus to the cytoplasm one day after in MPTP-treated mice
than in saline-treated mice (Fig. 5A–H, white arrows), which is signiﬁ-
cantly reduced in mice receiving HMGB1-neutralizing antibody (I–L,
Q) or glycyrrhizin (M–P, Q).
3.4. Neutralizing HMGB1 antibody reduces MPTP neurotoxicity
Next we assessed the effects of blocking HMGB1 on the level of dis-
ease in the MPTP mouse model. Mice were administered anti-HMGB1
antibody as described in Methods. Signiﬁcantly more TH-positive neu-
rons (58% in mice receiving neutralizing HMGB1 antibody versus 44%
in control mice) as well as Nissl-stained neurons (79% inmice receiving
neutralizingHMGB1antibody versus 59% in controlmice) survived after
MPTP treatment compared to untreated (Fig. 6A, B and supplemental
table 1). This difference was reﬂected by a signiﬁcantly less marked de-
crease in both the density of TH-positive ﬁbres (44 versus 14%, Fig. 6C),
and in dopamine levels (30% versus 18%, Fig. 6D) in the striatumofmice
treated with neutralizing HMGB1 antibody (Fig. 6C and supplemental
table 1). Determination of 1-methyl-4-phenylpyridinium(MPP+) levels
in the striatum after MPTP treatment with and without concomitantositive neurons in the SNpc are comparable between saline-treatedmice receiving and not
nt, mice initially treated with HMGB1-neutralizing antibody show higher numbers of TH-
y, depletion of striatal dopaminergic ﬁbres and striatal dopamine depletion assessed three
(C, D). Cell counts were performed with stereology. ODwas assessed by use of ScionImage
0.05, compared to respective, MPTP treated, mice groups which did not receive HMGB1
re presented with mean ± SEM. AB, antibody.
Table 3
Effect of HMGB1 neutralization on MPTP-induced astrocytic and microglial markers.
PD model Neuroprotection
No Anti-HMGB1 AB Anti-HMGB1 AB
Iba1-positive microglial cells Saline 5554 ± 52 5435 ± 105
MPTP 8084 ± 41⁎ 5797 ± 171
GFAP-positive astrocytes Saline 5853 ± 233 6149 ± 84
MPTP 8257 ± 306⁎ 6400 ± 211
Numbers of Iba1-positivemicroglial cells andGFAP-positive astrocytes in the SNpc ofmice
were signiﬁcantly increased 2 days afterMPTP, but remained fairly unchanged inmice re-
ceiving HMGB1 neutralizing antibody (Anti-HMGB1-AB). Data are mean± SEM. generat-
ed from 4 to 6 mice per group.
⁎ p b 0.05, compared to MPTP-treated mice receiving HMGB1 neutralizing antibody
(Newman–Keuls post-hoc test).
Table 2
1-Methyl-4-phenylpyridinium (MPP+) levels.
MPP+ [μg/g tissue]
MPTP + saline treatment 12.31 ± 2.9
MPTP + HMGB1 antibody treatment 10.49 ± 1.9
MPTP + glycyrrhizin 11.30 ± 1.4
MPP+ levels in striatum 90 min after MPTP treatment. Values are means ± SEM for four
mice per group. Groups were compared with Newman–Keuls post-hoc test (n.s.).
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did not impair MPTP metabolism (Table 2).
3.5. Neutralization of HMGB1 lowers RAGE and TNF-α levels in MPTP-
treated mice
Assessment of the inﬂuence of HMGB1 neutralizing antibody on
MPTP-induced effects in themousemidbrain by use of immunoblotting
(Fig. 7A) revealed signiﬁcantly lower RAGE protein levels in mice treat-
ed with HMGB1 antibody, compared to mice only receiving MPTP (Fig.
7B). Comparable results were obtained for TNF-α (Fig. 7C). In contrast,
COX-2 protein levels were not signiﬁcantly different between the
groups after MPTP administration (Fig. 7D). There were no signiﬁcant
differences in RAGE and TNF-α levels between saline treated groups
(data not shown).
3.6. Neuronal damage and microglial cell activation in MPTP-treated mice
is reduced when HMGB1 is neutralized
As HMGB1 is linked to inﬂammation, we assessed whether the pro-
tective effect of a neutralizing HMGB1 antibody is associated with a re-
duction of MPTP-induced microglial and astroglial cell activation.
Stereological counting showed that, compared to untreatedmice, treat-
ment of MPTP-mice with neutralizing antibody to HMGB1 prevented
both microglial cell activation (Iba1 positive cells) and gliosis (GFAP
positive cells) in the SNpc (Table 3).
3.7. Glycyrrhizin reduces MPTP toxicity dose-dependently
Wenext assessed whether the natural liquorice extract glycyrrhizin,
which is known to bind to HMGB1 had any neuroprotective effect in the
MPTP mouse model. Glycyrrhizin had a dose-dependent effect on
MPTP-induced toxicity in mice after three weeks of treatment (Fig. 8).
In mice treated with MPTP alone, 32% of TH-positive neurons (Fig. 8A,
C) in the SNpc, and 74% of the Nissl-positive neurons survived. In
MPTP-treatedmicewho received daily doses of 16.8mg/kg glycyrrhizin,
66% of TH-, and 84% of Nissl-stained neurons survived. Daily i.p. injec-
tion of 50 mg/kg glycyrrhizin led to a survival rate of 75% of the TH-Fig. 7.HMGB1 inﬂuencesMPTP toxicity via RAGE and TNF-α. Twodays afterMPTP treatment, im
also receiving HMGB1-neutralizing antibody, compared tomice not receiving the antibody. COX
mean ± SEM, n = 4–6 mice per group. *p b 0.05; ANOVA with student Newman–Keuls post-hpositive neurons (Fig. 8A, C), and 84% of the Nissl-stained neurons.
These results were conﬁrmed by optical density measures of TH-
positive ﬁbres in the striatum. In untreated mice, MPTP caused 80%
loss of TH-positive striatal ﬁbres, but in glycyrrhizin-treated mice this
was reduced to 53% and 37% loss of ﬁbres at doses of 16.8 mg/kg and
50 mg/kg respectively. (Fig. 8B, D).
To assess whether glycyrrhizin also inﬂuences striatal dopaminergic
dysfunction after MPTP treatment, dopamine, DOPAC and HVA levels
were determined in mouse striatal tissue (see supplemental table 2).
The data support a role for HMGB1 in causing damage to the dopami-
nergic system in MPTP treated mice, since application of glycyrrhizin
with increasing doses led to a dose dependent recovery of metabolites
levels aforementioned. Control experiments revealed that glycyrrhizin
per se did not inﬂuence the dopaminergic system. Detailed information
about MPP+ levels are provided in Table 2.
The effect of glycyrrhizin also appeared to be mediated via blockade
of HMGB1 protein is supported by the evidences of reducedHMGB1 and
RAGE protein levels in the midbrain of MPTP mice treated with
glycyrrhizin (Fig. 9). Interestingly, levels of a RAGE co-ligand, S100B
(Sathe et al., 2012), were not signiﬁcantly altered.
4. Discussion
This is, to the best of our knowledge, the ﬁrst study (i) showing
in vivo evidence that HMGB1 protein levels are altered in patients
with PD and that blocking HMGB1 in an animal model of PD is neuro-
protective, (ii) providing evidence of how HMGB1 contributes to the
progression of the disease by causing activation of microglia and in-
creased gliosis in the SNpc, and (iii) demonstrating that the damaging
effects of HMGB1 can be reduced by administration of the naturally oc-
curring HMGB1-binding compound glycyrrhizin.
Increased levels of HMGB1 protein in the SN, as well as in the CSF
and serum of PD patients support the hypothesis that HMGB1 ismunoblotting reveals higher levels of RAGE (A,B) and TNF-α protein (A,C) inmice initially
-2 protein levels are comparable between the differentially treated groups (A, D). Data are
oc test.
Fig. 8. Glycyrrhizin rescues dopaminergic neurons dose-dependently fromMPTP toxicity. Mice receiving initial i.p. glycyrrhizin show higher numbers of TH-positive neurons in the SNpc
(A, C) as well as more striatal dopamine-positive ﬁbres (B, D), than do mice without glycyrrhizin treatment three weeks after MPTP treatment. This effect is dose-dependent (A-D). Cell
counts were performedwith stereology. Optical density of striatal TH positive ﬁbres was assessed by use of Scion Image Scion Corp., Frederick, Maryland, USA). Striatal monoamine levels
were assessed byHPLC. *p b 0.05, **P b 0.01 compared to respectivemice groupswhich did not receive glycyrrhizin. Data are generatedwith sixmice per group. Values are presentedwith
mean ± SEM. n = 4–5 mice per group; ANOVA with student Newman–Keuls post-hoc test.
66 M. Santoro et al. / Neurobiology of Disease 91 (2016) 59–68involved in the pathogenesis of PD. The negative correlation of HMGB1
serum levels with age at onset of the disease suggests a speciﬁc effect of
the HMGB1 in PD pathogenesis; as, even though indirectly, earlier oc-
currence of the disease is associated with a more “speciﬁc” pathology
leading to clinical symptoms (de la Fuente-Fernández et al., 2011).
However, age at onset parameter shows only 1% (R2 = 0.01) of theFig. 9.Glycyrrhizin signiﬁcantly reducesMPTP-inducedHMGB1 and RAGE but not S100B levels
RAGE proteins one day after MPTP treatment are reduced inmice also receiving i.p. glycyrrhizin
dose of glycyrrhizin. S100B, another ligand of RAGE, did not show these changes. Low levels of
Data are mean ± SEM, n = 4–6 mice per group. *p b 0.05; ANOVA with student Newman–Keuvariance of the HMGB1 serum levels, so the negative correlation is
weak. The positive correlation of HMGB1 serum levels (R2 = 0.06)
with PD duration, shows a variance of 6% of HMGB1 levels. This provide
evidences in favour of an involvement of the protein in the previously
proposed uncontrolled inﬂammatory process in PD which, in concert
with dying neurons and pathological protein aggregates, leads to a. In the immunoblot of the ventral midbrain area containing the SNpc, levels of HMGB1 and
. This effect was dose-dependent and reached signiﬁcance in the group receiving the high
RAGE, TNF-α and COX-2 were detected in control mice receiving saline (data not shown).
ls post-hoc test.
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et al., 2013). Moreover, this positive association of HMGB1 levels with
disease duration argues for the existence of additional sources beyond
damaged and dying neurons in particular at advanced disease stage
where the number of potentially HMGB1-delivering (dopaminergic)
neurons is reduced as the disease progresses. HMGB1 was consistently
observed in the cytosol of TH-positive neurons in PD tissue, but not in
control tissue. Additionally MPTP-treated but not saline-treated mice
also regularly showed HMGB1 located in the neuronal cytoplasm, indi-
cating that translocation of HMGB1 from the nucleus to the cytoplasm is
increased in these animals. Although the process of HMGB1 secretion is
not entirely clariﬁed yet, we consider this process paramount for the in-
terpretation of our ﬁndings (Lu et al., 2014). HMGB1 in the ageing brain
has been considered as an inﬂammatory mediator, and high HMGB1
levels are associated with diverse mechanisms eventually leading to
progressive neuronal damage (Kim et al., 2006, Fang et al., 2012,
Muhammad et al., 2008, Takata et al., 2012).
The deleterious effects of HMGB1 induced byMPTP can be inhibited
by blocking HMGB1, supporting a role for HMGB1 in causing damage to
thedopaminergic systemafterMPTP treatment. In a recent study, Sasaki
and colleagues showed that HMGB1 inhibition viamonoclonal antibody
administration protects against 6-OHDA neurotoxicity in a rat model.
Moreover in support of our ﬁndings they showed reduced translocation
of HMGB1 from nuclei to cytoplasm after treatment with neutralizing
antibody (Sasaki et al., 2016). The observed effects in this study were,
at least partly, driven by upregulation and activation of the multi-
ligand receptor RAGE. We found that neutralization of HMGB1 in the
chronic MPTP mouse model led to reduced levels of RAGE and TNF-α
in combination with reduced dopaminergic damage, which indicates
that the downstream signalling cascades of RAGE, involvingNF-kB, con-
tribute to the damaging effect of HMGB1 (Ramasamy et al., 2005). Also,
prior studies have implicated HMGB1 exposure in up-regulating RAGE
(Andersson and Tracey, 2011, Schmidt et al., 2001), thus inhibition of
HMGB1 was likely the cause for the observed reduced expression of
RAGE.
Further downstream cascades known to be activated upon ligand–
RAGE interaction – such as erk1/2 (p44/p42) MAP kinases, p38 and
SAPK/JNKMAP kinases and the JAK/STAT pathway – aswell as addition-
al multi-ligand receptors (e.g. TLR 2 and 4, Mac1 receptor (Gao et al.,
2011, Andersson et al., 2008, Wahamaa et al., 2011)) are likely to con-
tribute to the HMGB1-mediated effect (Ramasamy et al., 2005). Indeed,
Mac1 expressed on the surface of microglia is a promising candidate for
additional HMGB1-mediated dopaminergic toxicity, as HMGB1 has re-
cently been shown to induce the production of multiple inﬂammatory
and neurotoxic factors via microglial Mac1 (Gao et al., 2011), and neu-
tralization of HMGB1 as performed in this study dramatically reduced
MPTP-induced gliosis. The cytosolic localization of HMGB1 in microglia
also suggests that not only HMGB1 released from dying dopaminergic
neurons but HMGB1 released frommicroglia contribute to the observed
HMGB1-induced cell death.
HMGB1mediated activation of RAGE leads to microglia recruitment
in a model of stroke (Muhammad et al., 2008). Additionally, a recent
work on HMGB1 implicates its oxidation state in inﬂammatory patho-
genesis, such that the oxidative damage associated with PD onset may
lead to conversion of the nuclear thiol HMGB1 to oxidized HMGB1,
which would enhance its inﬂammatory potential (Andersson and
Tracey, 2011).
Moreover, mechanisms beyond receptor activation may contribute
to the deleterious effects of HMGB1. HMGB1 is detectable in beta amy-
loid (Aβ) plaques, and high levels of HMGB1 are associated with im-
paired microglial phagocytosis of amyloid-beta1–40 (Takata et al.,
2012) and 1–42 (Takata et al., 2004) in the rat brain. Impairedmicroglial
phagocytosis as shown in the above models leads to delayed clearance
of the Aβ species and accelerated neurodegeneration. This is of interest
as (i) HMGB1 has been demonstrated to bind to native (Song et al.,
2014) and aggregated α-synuclein (Lindersson et al., 2004), and to bepresent in α-synuclein ﬁlament-containing Lewy bodies (Lindersson
et al., 2004), and (ii) α-synuclein can be released from neurons, and
this extracellular α-synuclein may even more effectively contribute to
progressive neurodegeneration, spreading of α-synuclein pathology,
and increased neuroinﬂammation, than intracellular α-synuclein does
(Lee et al., 2014). Although the interaction of (secreted) HMGB1 and
(secreted) α-synuclein is still hypothetical, we feel that, with the inﬂu-
ence of HMGB1 on neuroinﬂammation and neurodegeneration in the
MPTP model shown here, further in-depth studies on the interaction
of HMGB1 with different α-synuclein species are urgently needed.
5. Conclusion
In agreement with the results of previous studies showing a protec-
tive effect of glycyrrhizin in HMGB1-mediated injury (Musumeci et al.,
2014), our ﬁndings show a substantial reduction of MPTP-induced do-
paminergic neurodegeneration, due to inhibition of HMGB1 expression
and translocation, accompanied by reduced RAGE levels in midbrain
mouse tissue. The dose-dependency of the protective effect of
glycyrrhizin observed here indicates that the compound is a ﬁnely
tuneable inhibitor. This makes it, in our view, a promising candidate
for future controlled trials on neuromodulation in PD.
This study shows that HMGB1 is involved in PD, and pharmacologi-
cal inhibition of HMGB1 by use of neutralizing HMGB1 antibody as well
as glycyrrhizin in the MPTP model is neuroprotective.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.02.018.
Competing interests
Dr. Tracey has a patent Inhibitors of HMGB1 issued toMerck Serono.
All other authors declare that they have no competing ﬁnancial
interests.
Author contributions
WM, PT conceived and designed the experiments, performed exper-
iments, were involved in drafting and editing the manuscript, and
interpreted primary data. MS, PS, HLM, MAH, TWR, performed the ex-
periments. WM, TG, GR, JVF, DB, PT edited the manuscript. KJT contrib-
uted reagents. All authors read and approved the ﬁnal manuscript.
Acknowledgements
Samples were obtained from the Neuro Biobank of the University of
Tuebingen, Germany (http://www.hih-tuebingen.de/nd/biobank/for-
researchers/). This biobank is supported by the Hertie Institute and
the DZNE. We are grateful to the staff of the Medical Research Facility
for their help with the animal care. We thank Dr. Kinnari Sathe for her
help with the experiments. We thank Claire A. Walker for assisting
with western blot analysis. This study was supported by: Tenovus Scot-
land, Parkinson's Disease Foundation, Royal Society 2006/R1, NHS En-
dowment 14-42, and Wellcome Trust WT080782MF.
References
Abe, K., Ikeda, T., Wake, K., Sato, T., Sato, T., Inoue, H., 2008. Glycyrrhizin prevents of lipo-
polysaccharide/D-galactosamine-induced liver injury through down-regulation of
matrix metalloproteinase-9 in mice. J. Pharm. Pharmacol. 60, 91–97.
Andersson, U., Tracey, K.J., 2011. HMGB1 is a therapeutic target for sterile inﬂammation
and infection. Annu. Rev. Immunol. 29, 139–162.
Andersson, A., Covacu, R., Sunnemark, D., Danilov, A.I., Dal Bianco, A., Khademi, M.,
Wallstrom, E., Lobell, A., Brundin, L., Lassmann, H., Harris, R.A., 2008. Pivotal advance:
HMGB1 expression in active lesions of human and experimental multiple sclerosis.
J. Leukoc. Biol. 84, 1248–1255.
Bustin, M., Reeves, R., 1996. High-mobility-group chromosomal proteins: architectural
components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54,
35–100.
68 M. Santoro et al. / Neurobiology of Disease 91 (2016) 59–68de la Fuente-Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au,
W.L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., 2011. Age-speciﬁc progression
of nigrostriatal dysfunction in Parkinson's disease. Ann. Neurol. 69, 803–810.
Fang, P., Schachner, M., Shen, Y., 2012. HMGB1 in development and diseases of the central
nervous system. Mol. Neurobiol. 45, 499–506.
Gao, H.M., Liu, B., Zhang, W., Hong, J.S., 2003. Critical role of microglial NADPH oxidase-
derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17,
1954–1956.
Gao, H.M., Zhou, H., Zhang, F., Wilson, B.C., Kam, W., Hong, J.S., 2011. HMGB1 acts on mi-
crogliaMac1 tomediate chronic neuroinﬂammation that drives progressive neurode-
generation. J. Neurosci. 31, 1081–1092.
Hirsch, E.C., Hunot, S., 2009. Neuroinﬂammation in Parkinson's disease: a target for neu-
roprotection? Lancet Neurol. 8, 382–397.
Hirsch, E.C., Jenner, P., Przedborski, S., 2013. Pathogenesis of Parkinson's disease. Mov.
Disord. 28, 24–30.
Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., 1992. Accuracy of clinical diagnosis of idio-
pathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol.
Neurosurg. Psychiatry 55, 181–184.
Isbrucker, R.A., Burdock, G.A., 2006. Risk and safety assessment on the consumption of Lic-
orice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with empha-
sis on the pharmacology and toxicology of glycyrrhizin. Regul. Toxicol. Pharmacol. 46,
167–192.
Kim, Y.J., Lee, C.S., 2008. Glycyrrhizin attenuates MPTP neurotoxicity in mouse and MPP
-induced cell death in PC12 cells. Korean Journal of Physiology & Pharmacology 12,
65–71.
Kim, J.B., Sig Choi, J., Yu, Y.M., Nam, K., Piao, C.S., Kim, S.W., Lee, M.H., Han, P.L., Park, J.S.,
Lee, J.K., 2006. HMGB1, a novel cytokine-like mediator linking acute neuronal death
and delayed neuroinﬂammation in the postischemic brain. J. Neurosci. 26,
6413–6421.
Lee, H., Bae, E., Lee, S., 2014. Extracellular [alpha]-synuclein [mdash] a novel and crucial
factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98.
Lindersson, E.K., Højrup, P., Gai,W.P., Locker, D., Martin, D., Jensen, P.H., 2004.α-Synuclein
ﬁlaments bind the transcriptional regulator HMGB-1. Neuroreport 15, 2735–2739.
Lu, B., Antoine, D.J., Kwan, K., Lundback, P., Wahamaa, H., Schierbeck, H., Robinson, M.,
Van Zoelen, M.A., Yang, H., Li, J., Erlandsson-Harris, H., Chavan, S.S., Wang, H.,
Andersson, U., Tracey, K.J., 2014. JAK/STAT1 signaling promotes HMGB1
hyperacetylation and nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 111,
3068–3073.
Maetzler, W., Schmid, S.P., Wurster, I., Liepelt, I., Gaenslen, A., Gasser, T., Berg, D., 2011. Re-
duced but not oxidized cerebrospinal ﬂuid glutathione levels are lowered in Lewy
body diseases. Mov. Disord. 26, 176–181.
Mazarati, A., Maroso, M., Iori, V., Vezzani, A., Carli, M., 2011. High-mobility group box-1
impairs memory in mice through both toll-like receptor 4 and receptor for advanced
glycation end products. Exp. Neurol. 232, 143–148.
Medzhitov, R., 2008. Origin and physiological roles of inﬂammation. Nature 454, 428–435.
Muhammad, S., Barakat, W., Stoyanov, S., Murikinati, S., Yang, H., Tracey, K.J., Bendszus,
M., Rossetti, G., Nawroth, P.P., Bierhaus, A., Schwaninger, M., 2008. The HMGB1 recep-
tor RAGE mediates ischemic brain damage. J. Neurosci. 28, 12023–12031.
Musumeci, D., Roviello, G.N., Montesarchio, D., 2014. An overview on HMGB1 inhibitors
as potential therapeutic agents in HMGB1-related pathologies. Pharmacol. Ther.
141, 347–357.Ramasamy, R., Vannucci, S.J., Yan, S.S., Herold, K., Yan, S.F., Schmidt, A.M., 2005. Advanced
glycation end products and RAGE: a common thread in aging, diabetes, neurodegen-
eration, and inﬂammation. Glycobiology 15, 16R–28R.
Sasaki, T., Liu, K., Agari, T., Yasuhara, T., Morimoto, J., Okazaki, M., Takeuchi, H., Toyoshima,
A., Sasada, S., Shinko, A., 2016. Anti-highmobility group box 1 antibody exerts neuro-
protection in a rat model of Parkinson's disease. Exp. Neurol. 275, 220–231.
Sathe, K., Maetzler, W., Lang, J.D., Mounsey, R.B., Fleckenstein, C., Martin, H.L., Schulte, C.,
Mustafa, S., Synofzik, M., Vukovic, Z., Itohara, S., Berg, D., Teismann, P., 2012. S100B is
increased in Parkinson's disease and ablation protects against MPTP-induced toxicity
through the RAGE and TNF-alpha pathway. Brain 135, 3336–3347.
Scafﬁdi, P., Misteli, T., Bianchi, M.E., 2002. Release of chromatin protein HMGB1 by necrot-
ic cells triggers inﬂammation. Nature 418, 191–195.
Schmidt, A.M., Yan, S.D., Yan, S.F., Stern, D.M., 2001. The multiligand receptor RAGE as a
progression factor amplifying immune and inﬂammatory responses. J. Clin. Invest.
108, 949–955.
Song, J., Lu, J., Liu, L., Chen, L., Durairajan, S.S.K., Yue, Z., Zhang, H., Li, M., 2014. HMGB1 is
involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a pro-
cess modulated by the natural autophagy inducer corynoxine B. Autophagy 10,
144–154.
Stormer, F.C., Reistad, R., Alexander, J., 1993. Glycyrrhizic acid in liquorice–evaluation of
health hazard. Food Chem. Toxicol. 31, 303–312.
Sun, Q., Wang, F., Li, W., Li, W., Hu, Y.C., Li, S., Zhu, J.H., Zhou, M., Hang, C.H., 2013.
Glycyrrhizic acid confers neuroprotection after subarachnoid hemorrhage via inhibi-
tion of high mobility group box-1 protein: a hypothesis for novel therapy of sub-
arachnoid hemorrhage. Med. Hypotheses 81, 681–685.
Takata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T., Shimohama, S., 2004.
High mobility group box protein-1 inhibits microglial Aβ clearance and enhances
Aβ neurotoxicity. J. Neurosci. Res. 78, 880–891.
Takata, K., Takada, T., Ito, A., Asai, M., Tawa, M., Saito, Y., Ashihara, E., Tomimoto, H.,
Kitamura, Y., Shimohama, S., 2012. Microglial amyloid-β 1–40 phagocytosis dysfunc-
tion is caused by high-mobility group box protein-1: implications for the pathological
progression of Alzheimer's disease. Int. J. Alzheimers Dis. 2012.
Teismann, P., Schulz, J.B., 2004. Cellular pathology of Parkinson's disease: astrocytes, mi-
croglia and inﬂammation. Cell Tissue Res. 318, 149–161.
Wahamaa, H., Schierbeck, H., Hreggvidsdottir, H.S., Palmblad, K., Aveberger, A.,
Andersson, U., Harris, H.E., 2011. High mobility group box protein 1 in complex
with lipopolysaccharide or IL-1 promotes an increased inﬂammatory phenotype in
synovial ﬁbroblasts. Arthritis Res. Ther. 13, R136.
Xu, H., Chen, M., Forrester, J.V., 2009. Para-inﬂammation in the aging retina. Prog. Retin.
Eye Res. 28, 348–368.
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H.E., Susarla, S.M., Ulloa, L., Wang,
H., DiRaimo, R., Czura, C.J., Wang, H., Roth, J., Warren, H.S., Fink, M.P., Fenton, M.J.,
Andersson, U., Tracey, K.J., 2004. Reversing established sepsis with antagonists of en-
dogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101, 296–301.
Zhang, F., Qian, L., Flood, P.M., Shi, J.S., Hong, J.S., Gao, H.M., 2010. Inhibition of IkappaB
kinase-beta protects dopamine neurons against lipopolysaccharide-induced neuro-
toxicity. J. Pharmacol. Exp. Ther. 333, 822–833.
